Telix联手IBA/法马通合资公司Ekalia推进美国锕-211规模化生产，支撑早期α疗法管线TLX102-Tx

Telix Pharmaceuticals (TLX,TLX.AX) and Ekalia, a joint venture between IBA and Framatome, announced a collaboration to advance scalable United States production of astatine-211, or 211At, an alpha-emitting radioisotope being investigated for targeted alpha therapy. The alliance expands into the U.S. the strategic partnership formed by IBA and Framatome in Europe to advance industrial-scale At production. For Telix, the collaboration is expected to support the development of several early-stage therapeutic candidates, including TLX102-Tx, a targeted alpha therapy being evaluated for glioblastoma and leptomeningeal disease, as well as future 211At programs.
Chad Watkins, General Manager, Isotope Strategy at Telix, said: "This collaboration gives Telix a dedicated, long-term source of astatine-211 to advance our alpha therapy pipeline, and demonstrates the strategic value of the RLS platform as a host for next-generation isotope production in the U.S."
Telix shares are trading at A$15.40 on ASX, down 2.10%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.